Clinical trial · Interventional
Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal Tumours
Effects of Dexmedetomidine on Periprocedural Pain During Radiofrequency Ablation of Liver and Kidney Tumours
NCT02016391CI-TRIAL-00016362completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of he study is to evaluate effects of dexmedetomidine on pain during radiofrequency ablation of liver and kidney tumours.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer of Kidney and Renal Pelvis | — | UNRESOLVED | — |
| Cancer of Liver | Malignant Liver Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dexmedetomidine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Dexmedetomidine
- interventionNames
- Drug: Dexmedetomidine
Primary outcomes (1)
- measure
- Patient Satisfaction With Sedation Technique
- timeFrame
- After completion of procedure (within 15 minutes)
- description
- Rating of how satisfied the patient was with their sedation on a scale of 1-5 with 1 being very dissatisfied and 5 being extremely satisfied
Secondary outcomes (3)
- measure
- Vital signs: blood pressure, oxygen saturation, heart rate, breathing rate
- timeFrame
- During procedure and up to 2 hours stay at the post-anesthesia care unit
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * liver or/and kidney cancer for which radiofrequency ablation procedure is planned * signed informed consent form Exclusion Criteria: * patient refusal * pregnancy * known allergy to dexmedetomidine or remifentanil * atrioventricular block grade II or III or other significant cardiac conduction disturbance * stroke * low blood pressure not responding to treatment
References
Publications (0)
Data not yet available
No reference posted for this study.